Drugs / Remzistotug
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05277051 | Mar 2022 → Aug 2027 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06062420 | Nov 2023 → Sep 2026 expected | head and neck carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remzistotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277051 ↗ |
| Known as | GSK-4381562A | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068072 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068072 ↗ |